Format

Send to

Choose Destination
Radiother Oncol. 2017 Aug;124(2):271-276. doi: 10.1016/j.radonc.2017.06.024. Epub 2017 Jul 8.

A prospective study of proton reirradiation for recurrent and secondary soft tissue sarcoma.

Author information

1
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, United States. Electronic address: david.guttmann@uphs.upenn.edu.
2
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, United States.
3
Department of Radiation Oncology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, United States.
4
Division of Radiation Oncology, MD Anderson Cancer Center, Houston, United States.
5
Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, United States.

Abstract

BACKGROUND AND PURPOSE:

Proton reirradiation for sarcoma has not been previously described. We hypothesized that this strategy would provide favorable toxicity and survival outcomes.

MATERIAL AND METHODS:

Patients with soft tissue sarcoma in a previously-irradiated field were enrolled on a prospective trial of proton reirradiation. The primary endpoint was provider-reported acute toxicity. Secondary endpoints included late toxicities, local control, and overall survival.

RESULTS:

23 patients underwent proton reirradiation. Median time between radiation courses was 40.7months (range 10-272). No grade 4-5 toxicities were observed. One patient (4%) experienced acute grade 3 dysphagia. Common grade 2 acute toxicities were fatigue (26%), anorexia (17%), and urinary incontinence (13%). There were two grade 3 late wound infections (10%) and one grade 3 late wound complication (5%). Grade 2 late complications included lymphedema (10%), fracture (5%), and fibrosis (5%). At a median follow-up of 36months, the 3-year cumulative incidence of local failure was 41% (95% CI [20-63%]). Median overall survival and progression-free survival were 44 and 29months, respectively. In extremity patients, amputation was spared in 7/10 (70%).

CONCLUSIONS:

Proton reirradiation of recurrent/secondary soft tissue sarcomas is well tolerated. While longer follow-up is needed, early survival outcomes in this high-risk population are encouraging.

KEYWORDS:

Proton therapy; Reirradiation; Sarcoma

PMID:
28697854
DOI:
10.1016/j.radonc.2017.06.024
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center